Aviano

• Phase 2/3 Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer Ended
  2022-502196-31-00 10 2023-08-21 Advanced or Recurrent Endometrial Cancer
• A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-resistant Prostate Cancer (TAMARACK) Ended
  2022-501078-20-00 4 2023-05-15 Metastatic Castration-resistant Prostate Cancer
• A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination w … Ended
  2022-501451-87-00 9 2023-03-31 Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
• Relatlimab + Nivolumab in Pediatric and Young Adult Lymphomas (RELATIVITY-069) Ended
  2023-503715-14-00 9 2022-12-29 Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lym
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep … Ended
  2024-513230-38-00 5 2022-12-15 Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peri
• Neoadjuvant Chemotherapy followed by Pre-operative Chemoradiation and Consolidation Chemotherapy before Surgery in High Risk Rectal Cancer: … Ended
  2024-517183-31-00 4 2022-11-18 High Risk Rectal Cancer
• Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed S … Ended
  2024-513559-34-00 5 2022-07-19 Small Cell Lung Cancer (SCLC)
• An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed … Ended
  2024-512717-41-00 4 2021-10-01 Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
• Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit … Ended
  2023-508443-40-00 5 2020-12-18 Lung Cancer, Non-Small Cell
• Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC Ended
  2022-500785-10-00 5 2019-08-23 Metastatic Castration-Resistant Prostate Cancer
• Rituximab, bendamustine and cytarabine followed by venetoclax (V-RBAC) in high-risk elderly patients with mantle cell lymphoma (MCL) Ended
  2024-511533-35-00 4 2018-09-03 Mantle Cell Lymphoma
• Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic cas … Ended
  2024-511660-89-00 4 2017-06-09 metastatic castration resistant prostate cancer (mCRPC)
• A study of Ibrutinib in combination with Rituximab versus Placebo in combination with Rituximab in treatment of patients with Follicular Lym … Ended
  2023-507271-21-00 5 2017-04-11 Follicular Lymphoma
• Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended
  2024-514515-10-00 5 2016-06-16 Breast Cancer
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
• ROMIDEPSIN IN COMBINATION WITH CHOEP AS FIRST LINE TREATMENT BEFORE HEMATOPOIETIC STEM CELL TRANSPLANTATION IN YOUNG PATIENTS WITH NODAL PER … Ended
  2024-511639-83-00 9 2014-09-01 Anaplastic Large T-cell Lymphoma ALK negative
• THIS IS A CLINICAL STUDY WHICH EVALUATES TREATMENT WITH CHLORAMBUCIL AND RITUXIMAB FOLLOWED BY RITUXIMAB GIVEN UNDER THE SKIN IN PATIENTS W … Ended
  2023-507291-52-00 4 2014-03-24 Extranodal Marginal Zone Lymphoma
• A Study of Valemetostat Tosylate Plus Pembrolizumab versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations Ended
  2024-519671-26-00 9 Advanced or Metastatic Non-Small Cell Lung Cancer

Showing 193–210 of 210 trials